Mapping the Protein Landscape of Early Psychosis
FutureNeuro, the Research Ireland Centre for Translational Brain Science, announced on June 16, 2026 that it is launching a proteomics study at RCSI University of Medicine and Health Sciences. The project aims to uncover protein biomarkers that could guide personalized therapy for individuals experiencing their first episode of psychosis.
Wellness insights
Sawubona Healing Circles Offer Path to Collective Recovery from Racial Trauma
Turning Rejection Into a Roadmap: Guidance for Emerging Mental‑Health Leaders
Height: A Key to Unlocking Better Health Decisions
Weight Loss Predictors FoundThe study will recruit 250 patients across three Irish hospitals. Researchers will analyse blood samples using high‑resolution mass spectrometry to map protein expression patterns. By linking these patterns to treatment outcomes, the team hopes to predict which drugs will work best for each patient. „Current psychosis care relies on trial and error,” said Dr. Siobhan O’Leary, lead investigator. „Proteomics offers a molecular window into disease mechanisms, allowing us to move beyond one‑size‑fits‑all prescriptions.”
Initial work has identified over 1,500 distinct proteins in the plasma of patients with first‑episode psychosis. About 200 of these show significant differences compared to healthy controls. The research team will focus on proteins involved in inflammation, synaptic function, and neurotransmitter regulation. „Inflammatory markers have repeatedly surfaced in psychosis research,” noted Professor Liam Murphy, senior scientist at FutureNeuro. „If we can validate their predictive power, clinicians could intervene earlier and more precisely.”
Can Protein Signals Predict Treatment Response?
The trial will follow participants for twelve months, recording medication response, side‑effect profiles, and functional recovery. Data will be integrated with clinical assessments and neuroimaging results. The multidisciplinary team includes neurologists, psychiatrists, and bioinformaticians, all working to build a predictive algorithm. Funding comes from the Irish Health Research Board and a partnership with a biotech firm specializing in diagnostic platforms.
Early results suggest that certain protein signatures correlate with rapid symptom reduction when patients receive atypical antipsychotics. Conversely, other signatures hint at better outcomes with cognitive‑behavioral therapy combined with lower‑dose medication. „If these findings hold, we could tailor treatment plans within weeks rather than months,” Dr. O’Leary explained. The study also explores whether protein changes can flag adverse reactions before they become clinically apparent.
The team plans to publish a preliminary analysis by the end of 2027. If successful, the proteomics approach could be expanded to other psychiatric conditions, such as bipolar disorder and major depression. The ultimate goal is a clinical test that informs prescribing decisions at the point of care, reducing the burden of ineffective treatment cycles.
The launch of this proteomics trial marks a significant step toward precision psychiatry in Ireland. By linking molecular data to real‑world outcomes, FutureNeuro hopes to improve recovery rates and lower long‑term healthcare costs. Continued collaboration with international research hubs will be essential to validate findings and bring personalized psychosis care to patients worldwide.
Frequently Asked Questions
What is proteomics and why is it relevant to psychosis? Proteomics studies the full set of proteins in a biological sample. Proteins reflect active biological processes, offering clues about disease pathways that DNA or RNA alone cannot reveal.
How will the study affect current treatment guidelines? If specific protein markers reliably predict drug response, guidelines could incorporate biomarker testing to recommend first‑line therapies tailored to each patient’s molecular profile.
When might patients see the benefits of this research? Initial clinical tools could emerge within five years, pending validation. Wider adoption would depend on regulatory approval and integration into psychiatric practice.